News and Press
ACELYRIN, INC. Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
Affibody AB, and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a pre-specified interim analysis.
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
Series B led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital (a Citadel company), and Westlake Village BioPartners
ACELYRIN Announces Appointment of Patrick Machado, JD to Board of Directors
Mr. Machado has more than two decades of experience growing biopharmaceutical organizations from development through commercialization...
ACELYRIN Appoints Paul M. Peloso, MD, as Chief Medical Officer
ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development...